Clinical Trial Update: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 open-label randomized trial comparing Rituximab plus Lenalidomide versus Rituximab plus chemotherapy followed by Rituximab in previously untreated fol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED